Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02826772 · ClinicalTrials.gov registry record · Phase 1
Safety, Tolerability, and PK of GT0918 (Proxalutamide) in Subjects With Metastatic Castrate Prostate Cancer
A Phase 1 study of Metastatic Castrate Resistant Prostate Cancer (mCRPC), sponsored by Suzhou Kintor Pharmaceutical Inc,.
- Completed
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
- 6
- Study locations
NCT02826772 is a Phase 1 study of Metastatic Castrate Resistant Prostate Cancer (mCRPC) that has completed, run by Suzhou Kintor Pharmaceutical Inc,. The registered enrollment target is 40 participants, below the 237-participant average among 3 other Metastatic Castrate Resistant Prostate Cancer (mCRPC) trials with a reported enrollment target (83% lower). The trial reports 6 study locations across 6 states.
The verdict
NCT02826772, a Phase 1 study of Metastatic Castrate Resistant Prostate Cancer (mCRPC), has completed, sponsored by Suzhou Kintor Pharmaceutical Inc,.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
- 6
- Study locations
Study Summary
This was a Phase 1, multicenter, open-label, clinical trial in adult subjects with metastatic castrate resistant prostate cancer who progressed after both hormonal therapy (abiraterone or enzalutamide) and chemotherapy (docetaxel), or cannot tolerate either or both therapies. The study involved a Phase 1 dose escalation of oral GT0918 to evaluate its safety, tolerability, pharmacokinetics and pharmacodynamics.
Conditions Studied
Interventions
- DRUG GT0918
Study Locations (6)
Maryland
- Chesapeake Urology Research Associates - Towson
Nebraska
- G U Research Network - Omaha
Nevada
- Comprehensive Cancer Centers of Nevada - Las Vegas
New Jersey
- Rutgers University - New Brunswick
New York
- North Shore Hematology Oncology Associates - East Setauket
Ohio
- Gabrail Cancer Center Research - Canton
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2016-02-10 |
| Est. Completion | 2020-02-15 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02826772
The ClinicalTrials.gov registry entry for NCT02826772 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 237-participant average among 3 other Metastatic Castrate Resistant Prostate Cancer (mCRPC) trials with a reported enrollment target (83% lower). The listed sponsor is Suzhou Kintor Pharmaceutical Inc,, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Metastatic Castrate Resistant Prostate Cancer (mCRPC) appearing as the primary indexed condition, and to 1 intervention - of which GT0918 is the first listed.
NCT02826772 reports 6 study locations spanning 6 distinct geographic areas - top geographies include Maryland, Nebraska, Nevada.
Frequently Asked Questions
What is clinical trial NCT02826772 about?
NCT02826772 is a clinical study titled "Safety, Tolerability, and PK of GT0918 (Proxalutamide) in Subjects With Metastatic Castrate Prostate Cancer". This was a Phase 1, multicenter, open-label, clinical trial in adult subjects with metastatic castrate resistant prostate cancer who progressed after both hormonal therapy (abiraterone or enzalutamide) and chemotherapy (docetaxel), or cannot tolerate either or both therapies. The study involved a P...
What is the current status of trial NCT02826772?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2016-02-10. Estimated completion is 2020-02-15.
What conditions does trial NCT02826772 study?
This clinical trial studies the following conditions: Metastatic Castrate Resistant Prostate Cancer (mCRPC).
What interventions are being tested in trial NCT02826772?
The interventions under investigation include: GT0918 (DRUG).
Who is sponsoring clinical trial NCT02826772?
This trial is sponsored by Suzhou Kintor Pharmaceutical Inc,, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02826772 being conducted?
This trial has 6 study locations across Maryland, Nebraska, Nevada, New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Castrate Resistant Prostate Cancer (mCRPC)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of Alpha Radioligand Therapy AB001 in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)
RECRUITING · Phase 1
-
TmPSMA-02 in mCRPC
RECRUITING · Phase 1
-
A Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men With mCRPC Who Were Previously Treated With Abiraterone Acetate for Prostate Cancer (MEVPRO-1).
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.